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Abstract 
Purpose: Women with breast cancer are at increased risk of second malignancy (SM). However, the impact of race 
and the hormone receptor (HR) status of the primary breast tumor on risk of SM are not known. The purpose of this 
study is to analyze the incidence of SM in women with a history of breast cancer according to race and HR status.
Methods: In the surveillance, epidemiology, and end results database, multiple primary standardized incidence ratio 
sessions were used to compare the incidence of SM in women with a history breast cancer to the cancer incidence in 
the general population. Analyses of SM by age, race, and hormone-receptor status were performed using the abso-
lute excess risk (AER) and observed/expected (O/E) ratio.
Results: Younger black women (under the age of 50) were at greater risk of SM with an AER = 76.03 (O/E = 2.3, 95 % 
CI = 12.19–2.4) compared to younger white women who had an AER = 38.59 (O/E = 1.55, 95 % CI = 1.53–1.58). Older 
black women (50 years and older) had at an increased risk of SM with an AER = 42.26 (O/E = 1.3, 95 % CI = 1.26–1.34) 
compared to older white women who had an AER = 11.56 (O/E = 1.07, 95 % CI = 1.06–1.08). Second breast malig-
nancy is the predominant SM in both black and white women. Women with hormone-receptor (HR)-negative breast 
cancer had higher risk of SMs with an AER = 43.53 (O/E = 1.41, 95 % CI = 1.38– 0.145–3.31) compared to women with 
HR-positive disease with an AER = 21.43 (O/E = 1.17, 95 % CI = 1.16–0.1.18). In HR-negative women, younger black 
women had an AER = 96.46 (O/E = 2.99, 95 % CI = 2.70–3.31), younger white women had an AER = 66 (O/E = 2.25, 
95 % CI = 2.13–2.36), older black women had an AER = 58.58 (O/E = 1.45, 95 % CI = 1.34–1.57), and older white 
women had an AER = 20.88 (O/E = 1.14, 95 % CI = 1.11–1.18).
Conclusions: Black breast cancer survivors and women with HR-negative breast cancer are at increased risk of SM, 
which deserves further evaluation to understand the biological and clinical basis for this increased risk.
© 2016 Diab et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Women with breast cancer are at increased risk of second 
malignancies (SM) compared to the general population 
(Berrington de Gonzalez et  al. 2010; Schaapveld et  al. 
2008; Mellemkjaer et al. 2006). As a result of increasing 
use of adjuvant systemic and local therapies, breast can-
cer survival rates have improved significantly over the 
past several decades (5–7). However, prolonged survival 
times also can carry a burden of increasing SM in surviv-
ing patients.
Breast cancer is a heterogeneous disease with vary-
ing underlying genetic predispositions and environmen-
tal factors resulting in different biological subtypes. The 
same factors leading to this biological heterogeneity 
might also lead to differing risks of SM. In addition, racial 
differences in breast cancer tumor biology and genom-
ics as elegantly reviewed by Daly and Olopade (Daly and 
Olopade 2015), can lead to differences in the risk of SM. 
Compared to white (W) women, black (B) women with 
breast cancer are more likely to be younger at diagnosis 
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(Clarke et al. 2003), carry hormone receptor (HR)-nega-
tive breast cancer (Iqbal et  al. 2015), present with more 
advanced stage at diagnosis (Kurian et al. 2010), and have 
higher rates of BRCA1/2 mutations or polymorphisms 
(John et  al. 2007; Nanda et  al. 2005). These clinical and 
biological differences might also impact the risk of SM. 
After a first primary breast cancer, no large population-
based study has investigated risk of SM by primary breast 
cancer subtype or race (Molina-Montes et al. 2015).
Based on the differences in the biology and outcomes 
among the races with breast cancer, and the heterogene-
ity of breast cancer in general, we hypothesize that the 
risks of SM are different based on race and the biologi-
cal subtype of breast cancer. Specifically, we character-
ized the risk of SMs in patients with a first diagnosis of 
breast cancer in the surveillance, epidemiology, and end 
results (SEER) database. We evaluated the risk based on 
age, race, and HR status.
Methods
Study population
The results reported in this study are based on the fol-
lowing SEER database: Incidence—SEER 9 Regs 
Research Data, Nov 2014 Sub (1973–2012) <Katrina/
Rita Population Adjustment >—linked to county attrib-
utes—Total U.S., 1969–2013 Counties, National Can-
cer Institute, DCCPS, Surveillance Research Program, 
Surveillance Systems Branch, released April 2015, based 
on the November 2014 submission. This database cov-
ers approximately 9.4 % of the US population (based on 
2010 census) and the geographic areas and years cov-
ered are: San Francisco-Oakland SMSA—1973+; Con-
necticut—1973+; Detroit (Metropolitan)—1973+; 
Hawaii—1973+; Iowa—1973+; New Mexico—1973+; 
Seattle (Puget Sound)—1974+; Utah—1973+; and 
Atlanta (Metropolitan)—1975+.
Multiple primary standardized incidence ratios (MP-
SIR) sessions were generated to compare incidence of SM 
in the SEER cohort of patients previously diagnosed with 
breast cancer to the incidence of cancer in the general 
population. The general population was matched by race 
and age.
The first primary diagnosis of breast cancer was used 
and patients were excluded if the diagnosis was obtained 
solely based on death certificate or autopsy report or 
if there was no microscopic confirmation of diagno-
sis. Patients with carcinoma in  situ were also excluded. 
Patients were observed from the diagnosis of breast can-
cer until the diagnosis of another cancer or death. For 
the analyses based on hormone receptors (HR), women 
for whom the summary results of estrogen and/or pro-
gesterone receptors were coded as positive or negative in 
the database were selected. Women whose breast cancer 
was coded as ER and PR borderline, undetermined, or 
unknown were excluded. Women with ER-positive or 
PR-positive cancer were analyzed together as HR-pos-
itive disease. For the race analyses, the SEER variables 
white and black were selected, and other or unknown 
races were excluded. The terms younger (Y) women and 
older (O) women in this manuscript refer to women 
under age 50 and 50 years or older, respectively. The risk 
of SM are reported for younger white (YW), younger 
black (YB), older white (OW), and older black (OB). Due 
to the limited data on HER2 status in the SEER database, 
the impact of this variable on the risk of SM was not 
examined.
Statistical analyses
SEER* Stat 8.2.1, released on 4/08/2015, was used to 
analyze the observed to expected (O/E) risk of second-
ary cancers in patients with a first breast cancer diagno-
sis. The observed incidence is the actual count of events 
experienced for this subset of patients. The expected 
incidence is the number of events expected for this sub-
set of general population of women matched by race 
and age. The O/E risk is the observed count divided by 
the expected count. The absolute excess risk (AER) is 
the excess cancer (beyond the expected amount) per 
10,000 persons per year. The formula for excess risk is: 
(Observed count—Expected count)  ×  10,000/person 
years at risk. The mean age at exposure is the mean age, 
in years, at diagnosis of the first cancer among individu-
als in this subset of the cohort, and the mean age at event 
is the mean age, in years, at the time of experiencing the 
SM. 95 % confidence intervals (CI) are reported and the P 
value is <0.05 if the CIs do not overlap 1.
Results
Risk of SM by age
Women with a first diagnosis of breast cancer have a sig-
nificant increased risk of SM at all sites with higher risk 
in younger women.
Younger women (n =  126,689, mean age 42.78  years) 
had 16,492 new SM (AER  =  43.06, O/E  =  1.64, 95  % 
CI  =  1.62–1.67), and the mean age at time of SM was 
54.6 years. In contrast, older women (n = 387,790, mean 
age 67.2 years) had 58,378 SM (AER = 15.01, O/E = 1.10, 
95 % CI =  1.09–1.11), and the mean age at time of SM 
was 74.4 years.
Younger women had 8696 new second breast malig-
nancy (SBM) (AER = 33.49, O/E = 2.37 95 % CI = 2.32–
2.42), and the mean age of SBM was 52.4 while older 
women had 19.175 SBM (AER = 14.45, O/E = 1.36 95 % 
CI = 1.34–1.37) and the mean age of SBC was 72.8.
For younger women, the AER was significant for solid 
tumors (41.91), SBM (33.49), ovarian (2.39), respiratory 
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system (2.29), leukemia (1.11), uterine (1.05), skin (0.61), 
endocrine cancers (0.57), urinary systems (0.4), soft tis-
sue (0.39), pancreas (0.28), and bone/joint (0.08). For 
OW, the AER was significant for solid tumors (17.32), 
SBM (14.45), gynecologic (3.17), skin (0.48), endocrine 
cancers (0.51), urinary systems (0.4), soft tissue (0.27), 
and bone/joint (0.08).
Risk of SM by race
BW women with a first diagnosis of breast cancer had 
an increased risk of SM compared with WW women 
regardless of age. YB women (n  =  14,888, mean age 
41.82 years) had 1897 new SM (AER = 76.03, O/E = 2.3, 
95  % CI  =  12.19–2.4) and the mean age at time of 
SM was 52.0  years; YW women (n  =  99,946, mean 
age 42.95  years) had 13,390 new SM (AER  =  38.59, 
O/E =  1.55, 95 % CI =  1.53, 1.58) and the mean age at 
time of SM was 55.1  years. OB women (n  =  29,125, 
mean age 71.99 years) had 3818 new SM (AER = 42.26, 
O/E  =  1.3, 95  % CI  =  1.26–1.34) and the mean age at 
time of SM was 52.0  years; OW women (n  =  334,400, 
mean age 67.5) had 51,548 new SCs (AER  =  11.56, 
O/E = 1.07, CI = 1.06–1.08) and the mean age at time of 
SCs was 74.7 years (Table 1).
Second breast malignancy was a primary cause of 
increased risk of SC in both BW women and WW 
women. The AER for SBM in YB women and YW women 
was 61.0 and 30.2, respectively, and 31.3 and 12.7 for OB 
women and OW women, respectively.
When the analyses were limited to non-breast SM 
(NBSM), YB women had 743 new NBSM (AER = 15.05, 
O/E  =  1.4, 95  % CI  =  1.3–1.5) and the mean age at 
time of SM was 55.2; YW women had 6508 NBSM 
(AER = 8.43, O/E = 1.19, 95 % CI = 1.16–1.22) and the 
mean age at time of SCs was 57.38. OB women had 2439 
NBSC (AER = 10.95, O/E = 1.10, 95 % CI = 1.06–1.15) 
and the mean age at time of SMs was 73.20; OW women 
had 34,819 NBSM (AER = −1.1, O/E = 0.99, CI = 0.98–
1.0) and the mean age at time of SCs was 75.4.
Risk of second malignancy by hormone‑receptor status
Women with HR-negative breast cancer had higher risk 
of SM. Women with HR-negative disease (N  =  65,593) 
had 7442 new SM (AER  =  43.53, O/E  =  1.41, 95  % 
CI  =  1.38– 0.145–3.31) while women with HR-pos-
itive disease (N  =  9239,655) had 27,328 new SM 
(AER  =  21.43, O/E  =  1.17, 95  % CI  =  1.16–0.1.18) 
(Tables 2, 3, 4, 5, 6).  
Table 1 Risk of second cancer by age
#  Indicates P value <0.05
Under 50 50 and older
Observed O/E Excess risk Mean age 
at event
Observed O/E Excess risk Mean age 
at event
All sites 16,492 1.64# 43.06 54.64 58,378 1.10# 15.01 74.42
All solid tumors 15,479 1.68# 41.91 54.48 52,829 1.13# 17.32 74.2
Oral cavity and pharynx 204 1.25# 0.27 55.68 915 1.04 0.11 74.1
Digestive system 1481 1.07# 0.61 59.52 11,942 0.98 −0.6 77.01
Colon, rectum and anus 808 0.94 −0.36 59.13 7569 0.98 −0.34 77.15
Pancreas 237 1.22# 0.28 60.83 1734 0.95# −0.28 77.03
Peritoneum, omentum and mesentery 45 2.04# 0.15 59.65 110 0.94 −0.02 74.85
Respiratory system 1555 1.28# 2.29 59.76 7790 0.97# −0.78 74.11
Bones and joints 25 2.01# 0.08 53.86 50 1.1 0.01 72.67
Soft tissue including heart 110 2.14# 0.39 54.64 334 1.39# 0.27 74.43
Skin excluding basal and squamous 525 1.21# 0.61 54.16 1604 1.12# 0.48 74.49
Breast 8696 2.37# 33.49 52.44 19,175 1.36# 14.45 72.76
Female genital system 1877 1.35# 3.21 54.84 6909 1.19# 3.17 73.36
Corpus and uterus, NOS 903 1.21# 1.05 56.38 4262 1.36# 3.26 73.25
Ovary 720 1.99# 2.39 53.05 1785 1.07# 0.32 72.97
Urinary system 469 1.14# 0.4 59.24 2997 1.04 0.29 75.86
Brain and other nervous system 120 1.06 0.04 54.58 395 0.75# −0.37 72.7
Endocrine system 429 1.25# 0.57 52.14 806 1.28# 0.51 69.21
Lymphoma 361 0.94 −0.16 58.64 2145 0.91# −0.63 76.54
Leukemia 352 1.90# 1.11 53.62 1551 1.08# 0.31 75.51
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In women with HR-negative disease, YB women 
(N = 3578) had 370 new SM (AER = 96.46, O/E = 2.99, 
95 % CI = 2.70–3.31), YW women (N = 14,087) had 1485 
SM (AER  =  66.00, O/E  =  2.25, 95  % CI  =  2.13–2.36), 
OB women (N = 3578) had 590 new SM (AER = 58.58, 
O/E  =  1.45, 95  % CI  =  1.34–1.57), and OW women 
(N =  30,117) had 3520 SM (AER =  20.88, O/E =  1.14, 
95 % CI = 1.11–1.18).
In women with HR-positive disease, YB women 
(N = 5782) had 476 new SC (AER = 63.89, O/E = 2.29, 
95 % CI = 2.09–2.5), YW women (N = 3829) had 1485 
SC (AER = 36.87, O/E = 1.64, 95 % CI = 1.59–1.7), OB 
women (N =  12,689) had 1380 new SM (AER =  35.74, 
O/E  =  1.25, 95  % CI  =  1.19–1.32), and OW women 
(N = 161,244) had 20,547 SC (AER = 12.00, O/E = 1.08, 
95 % CI = 1.06–1.09).  
Risk of second breast malignancy in women with first 
non‑breast malignancy
The risk of breast cancer as a second event (BCSE) after 
a first diagnosis of non-breast cancer was evaluated. 
Having reciprocal increased risk supports the pres-
ence of shared etiology for both cancers. Black women 
(n  =  92,160) had 1508 new breast cancers as a second 
event (AER = 3, O/E = 1.11, 95 % CI = 1.06–1.17) while 
the risk was not elevated in white women when all sites 
of first cancers are grouped together.
In black women, the risk of SBM was elevated in 
women with non-basal/non-squamous skin cancer 
(n  =  40, AER  =  20.31, O/E  =  1.93), ovarian cancer 
(n = 69, AER = 8.47, O/E = 1.36), thyroid cancer (n = 87, 
AER  =  6.62, O/E  =  1.3), and lymphoma (n  =  110, 
AER = 8.66, O/E = 1.39).
In white women, the risk of SBM was elevated in 
women with soft tissue cancer (n  =  196, AER  =  4.11, 
O/E  =  1.16), non-basal/non-squamous skin can-
cer (n  =  2015, AER  =  1.64, O/E  =  1.06), thyroid 
(n =  1245 =  , AER =  3.0, O/E =  1.13), and lymphoma 
(n  =  1553, AER  =  3.45, O/E, 1.12), but not ovarian 
cancer.
Discussion
To our knowledge, this is the first detailed report dem-
onstrating an increased risk of SM in patients with pri-
mary breast cancer based on race, and HR status of breast 
cancer. The risk of SM was higher in black women than 
white women for both SBM and NBSM. This higher risk 
of SM in black women and HR-negative women might be 
Table 2 Second cancers by race
#  Indicates P value <0.05
Under 50 50 and older
White Black White Black
O/E Excess risk O/E Excess risk O/E Excess risk O/E Excess risk
All sites 1.55# 38.59 2.30# 76.03 1.07# 11.56 1.30# 42.26
All solid tumors 1.59# 37.78 2.37# 72.87 1.10# 14.23 1.34# 42.99
Oral cavity and pharynx 1.25# 0.28 0.98 −0.02 1.05 0.12 0.93 −0.13
Digestive system 1.04 0.35 1.08 0.87 0.97# −1.18 1.10# 3.71
Colon, rectum and anus 0.91# −0.53 0.98 −0.12 0.97# −0.62 1.07 1.51
Pancreas 1.17# 0.23 1.04 0.06 0.92# −0.39 1.07 0.47
Peritoneum, omentum and mesentery 2.11# 0.18 1.96 0.07 0.92 −0.03 1.06 0.01
Respiratory system 1.23# 1.93 1.69# 5.53 0.95# −1.1 1.08 1.73
Bones and joints 1.93# 0.08 2.04 0.07 1.1 0.01 1.22 0.03
Soft tissue including heart 2.16# 0.4 1.81 0.32 1.34# 0.24 1.75# 0.54
Skin excluding basal and squamous 1.20# 0.67 2.03 0.29 1.11# 0.51 1.71# 0.38
Breast 2.18# 30.16 3.91# 60.98 1.30# 12.67 1.89# 31.31
Female genital system 1.32# 3.14 1.47# 3.36 1.17# 2.93 1.22# 3.41
Corpus and uterus, NOS 1.16# 0.84 1.70# 2.24 1.32# 3.02 1.48# 3.69
Ovary 1.97# 2.5 2.00# 1.49 1.07# 0.33 0.97 -0.12
Urinary system 1.13# 0.38 1.14 0.32 1.02 0.19 1.23# 1.68
Brain and other nervous system 1.12 0.1 0.17# −0.34 0.75# -0.4 0.75 −0.23
Endocrine system 1.15# 0.35 2.00# 1.53 1.25# 0.45 1.50# 0.82
Lymphoma 0.93 -0.19 0.96 -0.07 0.89# -0.77 1.04 0.16
Leukemia 1.63# 0.84 3.95# 2.65 1.05 0.23 1.19 0.58
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Table 3 Second cancers in white and black women under 50 with hormone receptor-negative breast cancer
#  Indicates P value <0.05
White Black
O/E Excess risk Mean age at event O/E Excess risk Mean age at event
All sites 2.25# 66 50.07 2.99# 96.46 48.24
All solid tumors 2.29# 63.39 50.01 3.08# 91.44 48.18
Oral cavity and pharynx 2.35# 1.06 51.39 1.91 0.75 54.79
Digestive system 1.09 0.54 52.48 0.87 −1.07 49.84
Colon, rectum and anus 0.81 −0.68 51.86 0.85 −0.77 49.24
Pancreas 0.85 −0.12 47.3 0.37 −0.66 46.42
Peritoneum, omentum and mesentery 8.12# 0.77 53.12 14.86# 0.73 53.09
Respiratory system 1.43# 1.9 52.75 1.99# 5.44 50.75
Bones and joints 2.71 0.15 55.17 0 −0.07
Soft tissue including heart 4.07# 0.91 52.07 1.07 0.03 32.57
Skin excluding basal and squamous 1.21 0.73 50.86 1.47 0.12 61.09
Breast 3.31# 48.31 49.09 5.16# 78.93 47.01
Female genital system 2.16# 8.9 51.33 2.21# 7.06 53.27
Corpus and uterus, NOS 1.39# 1.59 54.44 2.06# 2.82 57.54
Ovary 4.60# 6.89 49.84 3.85# 3.48 47.03
Urinary system 1.4 0.78 51.42 0.45 −0.95 54.83
Brain and other nervous system 1.09 0.06 51.41 1.14 0.05 58.33
Endocrine system 1.04 0.12 47.93 1.61 1.04 44.75
Lymphoma 1.07 0.14 53.84 1.09 0.16 53.3
Leukemia 3.00# 1.82 47.71 8.48# 5.18 47.61
Table 4 Second cancers in white and black women 50 years and older with hormone receptor-negative breast cancer
#  Indicates P value <0.05
White Black
O/E Excess risk Mean age at event O/E excess risk Mean age at event
All sites 1.14# 20.88 72.06 1.45# 58.58 68.42
All solid tumors 1.17# 22.32 71.85 1.49# 57.08 68.31
Oral cavity and pharynx 1.05 0.1 70.44 0.75 −0.42 70.85
Digestive system 1 0.09 75.33 1.26# 8.2 70.81
Colon, rectum and anus 0.96 −0.76 75.73 1.14 2.55 70.63
Pancreas 0.98 −0.11 76.25 1.47 2.67 68.67
Peritoneum, omentum and mesentery 1.16 0.07 69.36 0 −0.22
Respiratory system 1.18# 4.15 72.59 1.25# 5.51 68.75
Bones and joints 0.75 −0.03 67.09 2.79 0.21 71.17
Soft tissue including heart 1.37 0.25 71.3 1.37 0.26 67.22
Skin excluding basal and squamous 1.06 0.33 71.19 1.9 0.45 68.58
Breast 1.37# 15.12 70.74 2.04# 36.73 67.02
Female genital system 1.18# 2.91 70.41 1.25 3.56 67.77
Corpus and uterus, NOS 1.23# 2.07 70.72 1.67# 5.39 67.91
Ovary 1.30# 1.37 69.62 0.7 −0.96 60.84
Urinary system 0.95 −0.44 72.29 1.23 1.58 68.57
Brain and other nervous system 0.78 −0.33 69.23 1.51 0.43 72.63
Endocrine system 1.19 0.47 65.7 1.4 0.82 61.22
Lymphoma 0.88 −0.8 74.86 1.31 1.21 65.59
Leukemia 1.2 0.77 71.68 1.35 0.92 72.13
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Table 5 Second cancers in white and black women under 50 with hormone receptor-positive breast cancer
#  Indicates P value <0.05
White Black
O/E Excess risk Mean age at event O/E Excess risk Mean age at event
All sites 1.64# 36.87 52.03 2.29# 63.89 50.76
All solid tumors 1.67# 35.63 52.08 2.34# 60.24 50.54
Oral cavity and pharynx 1.57# 0.49 53.33 0.29 -0.59 63
Digestive system 1.05 0.32 54.15 1.25 2.19 51.39
Colon, rectum and anus 0.9 −0.42 53.03 1.05 0.24 50.74
Pancreas 1.41# 0.35 56.16 1.33 0.35 56
Peritoneum, omentum and mesentery 1.42 0.05 56.73 0 −0.05
Respiratory system 1.37# 1.83 55.38 1.56# 3.15 52.2
Bones and joints 1.62 0.06 47.4 3.69 0.17 49.25
Soft tissue including heart 1.96# 0.3 51.14 1.91 0.34 51.53
Skin excluding basal and squamous 1.42# 1.48 50.76 3.58 0.69 53.21
Breast 2.22# 27.6 51.43 3.53# 49.01 49.75
Female genital system 1.24# 1.97 52.87 1.32 1.91 55.19
Corpus and uterus, NOS 1.39# 1.78 54.02 1.84# 2.28 56.48
Ovary 1.23# 0.48 51.05 0.96 −0.06 49.73
Urinary system 1.35# 0.75 54.28 1.88# 1.56 51.6
Brain and other nervous system 1.40# 0.28 51.19 0 −0.35
Endocrine system 1.26# 0.78 49.27 2.58# 2.77 47.17
Lymphoma 1.04 0.09 53.13 1.04 0.08 54.76
Myeloma 0.94 −0.03 56.76 1.14 0.15 57.99
Leukemia 1.89# 0.88 47.48 3.04# 1.44 52.46
Table 6 Second cancers in white and black women 50 years and older with hormone receptor-positive breast cancer
#  Indicates P value <0.05
White Black
O/E Excess risk Mean age at event O/E Excess risk Mean age at event
All sites 1.08# 12 74.31 1.25# 35.74 72.08
All solid tumors 1.10# 13.55 74.12 1.29# 36.26 71.94
Oral cavity and pharynx 1.07 0.16 74.7 1.24 0.43 72.9
Digestive system 0.99 −0.38 76.81 1.01 0.39 74.51
Colon, rectum and anus 1 0.09 77 0.97 −0.51 75.17
Pancreas 0.98 −0.12 76.64 1.05 0.33 73.4
Peritoneum, omentum and mesentery 1.02 0.01 75.19 1.15 0.03 63.92
Respiratory system 0.99 −0.37 74.44 1.02 0.48 72.78
Bones and joints 1.05 0.01 73 2.02 0.13 69
Soft tissue including heart 1.29# 0.22 74.04 1.92 0.68 68.95
Skin excluding basal and squamous 1.11# 0.61 73.4 2.54# 0.86 77.64
Breast 1.21# 8.91 72.86 1.74# 27.13 69.99
Female genital system 1.22# 3.64 73.5 1.27# 4.04 71.31
Corpus and uterus, NOS 1.43# 3.91 73.17 1.49# 4.03 71.26
Ovary 1.01 0.05 73.69 1.11 0.37 70.41
Urinary system 1.07# 0.62 74.99 1.23 1.74 74.27
Brain and other nervous system 0.80# −0.32 73.04 0.56 -0.4 77.34
Endocrine system 1.34# 0.77 68.5 1.69# 1.37 69.28
Lymphoma 0.89# −0.8 75.96 0.91 −0.37 70.93
Leukemia 1.15# 0.62 75.06 1.39 1.19 71.48
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related to underlying genetic variation in DNA repair. In 
a population-based, multi-ethnic series of female breast 
cancer patients <65 years at diagnosis who were enrolled 
at the Northern California site of the Breast Cancer Fam-
ily Registry, the BRCA1 mutation frequency was 16.7 % in 
black women diagnosed under age 35 versus 7.2 % in non-
Hispanic white patients without Ashkenazi Jewish ances-
try. Women with triple-negative breast cancer have higher 
frequency of BRCA1/2 mutation as well. The potential for 
higher frequency of impaired DNA repair mechanisms in 
black women and in HR-negative women (Bartkova et al. 
2008) might lead to poor DNA repair after exposure to 
radiation and systemic therapy and an increased risk of 
SM. In addition, it is known that higher body mass index 
is associated with higher incidence of cancer (Renehan 
et al. 2008; Bhaskaran et al. 2014). BW with breast cancer 
have been shown to have statistically more comorbidities 
and higher average body mass index (Tammemagi et  al. 
2005). Therefore, weight and other comorbidities, which 
were not controlled-for in this analysis, may play a role in 
the statistically increased risk of SM.
The strength of the SEER database for statistical analy-
sis is the long-term follow-up of large numbers of women 
with breast cancer, the availability of data on hormone 
receptor status and race, and the high quality of the data-
base itself. The SEER Program is viewed as the standard 
for quality among cancer registries around the world. 
Each SEER program registry must meet specifically 
defined data quality goals on an ongoing basis (http://
seer.cancer.gov).
However, the SEER registry is limited in that it does 
not report data on the use of adjuvant systemic therapy. 
Thus, the role of these therapies in the risk of SM cannot 
be elucidated and is a limitation of the current analyses. 
Data pertaining to HR status within SEER dates back 
only to 1990, limiting the number of women with com-
plete HR status. In addition, comorbidities and additional 
risk factors known to influence cancer incidence, such as 
body mass index, tobacco or alcohol consumption, physi-
cal activity, use of exogenous hormones, diet, and medi-
cations or supplements were not controlled-for in this 
analysis because the SEER database does not capture this 
information. Other limitations of the SEER (Curtis 2006) 
that might lead to overestimation or underestimation of 
the risk of SM include medical surveillance bias (greater 
surveillance of women with breast cancer compared to 
the general population leading to ascertainment bias), 
multiple comparisons leading to statistically significant 
increased risk that may have occurred by chance alone, 
and the contamination of the risk of SM by distant recur-
rence which can be falsely coded as second cancer, as well 
as underreporting of treatment received such as radia-
tion, and lack of capture of SM in index cases who leave 
the original SEER geographic location may also have con-
founded our results.
Testing for genetic predisposition to inherited cancer 
syndromes is evolving rapidly (Tung et al. 2015); however, 
black women are under-represented in studies evaluating 
inherited cancer syndromes. In the study by Tung et al. 
(2015), black women represented only approximately 5 % 
of the individuals tested. Our finding that black women 
are at an increased risk of second cancer suggests that 
this population would likely benefit from more genetic 
evaluation and counseling after a primary breast cancer 
diagnosis. Race is currently not a factor in NCCN guide-
lines for genetic counseling, but based on our findings, 
consideration should be given towards including race in 
evaluating genetic breast cancer risk.
Furthermore, with the increasing use of germline panel 
testing for inherited cancer syndromes, there is a clinical 
need for correlation between genotype and phenotype. 
We recommend that large databases such as SEER con-
sider collecting data on BRCA1 and BRCA2 and other 
inherited cancer predisposition genes, since the large 
clinical information available in SEER provides an excel-
lent opportunity for a better understanding of the risk of 
SM based on specific DNA repair genes.
The search for biological surrogate markers to identify 
tumors with abnormalities in DNA repair is underway 
(Watkins et  al. 2014). Homologues recombination defi-
ciency (HRD) score is a potential biological maker for 
impaired DNA repair (Watkins et  al. 2014). A potential 
correlation between the HRD score of a primary breast 
cancer and risk of secondary cancers deserves future 
exploration. The ability to identify patients who might be 
at higher risk for SM can have implications for primary 
therapy for the initial breast cancer, such as consideration 
for prophylactic surgery.
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